Case Report
The Efficacy and Safety of Rituximab in a Patient with Rheumatoid Spondylitis
Table 1
Clinical and laboratory findings in rheumatoid spondylitis patient before and after rituximab therapy.
| | | Baseline | 6 months | 12 months |
| | Tender joint count | 15 | 6 | 2 | | Swollen joint count | 8 | 1 | 0 | | BASDAI, 0–10 cm | 7.8 | 5.6 | 4.2 | | BASFI, 0–10 cm | 7.0 | 6.4 | 4.7 | | DAS28 | 5.4 | 3.5 | 2.02 | | Schober test (cm) | 2 | 2 | 2 | | Occiput-wall distance (cm) | 3 | 3 | 3 | | Chest expansion (cm) | 3 | 3 | 3 | | Finger-floor distance (10 cm) | 8 | 9 | 12 | | VAS patient global health, 0–100 mm | 95 | 54 | 33 | | VAS physician’s global assessment | 90 | 45 | 40 | | ESR, mm/h | 98 | 45 | 38 | | CRP, mg/dL (normal value 0–0.5 mg/dL) | 14.3 | 3.5 | 0.1 |
|
|
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index.
BASFI: Bath Ankylosing Spondylitis Functional Index.
|
